Industries Market Research Reports

Subscribe to RSS Feed
  1. 26 Aug 2024  |  Global  |  Market Research

    Precision Neurodegenerative Disease Market, Global, 2024 2028

    Precision NDD Treatment is Experiencing Transformational Growth due to AI Capabilities, Disease-modifying Therapies, and Industry Convergence

    The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarke...

    $2,450.00
  2. 22 Aug 2024  |  Global  |  Technology Research

    Pipeline Assessment for Cardiovascular Diseases

    Advanced Drug Modalities Fuel Cardiovascular Therapeutics Future Growth Potential

    Globally, CVD is the leading cause of death, with resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled. Traditional pharmacotherapy faces the drawbac...

    $4,950.00
  3. 20 Aug 2024  |  Global  |  Technology Research

    Technological Advances in Regenerative Medicine

    Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

    Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mese...

    $4,950.00
  4. 05 Aug 2024  |  Global  |  Technology Research

    CGT Research Outlook and Technology Growth Opportunities

    CGT Landscape Assessment

    The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, a...

    $4,950.00
  5. 15 Jul 2024  |  Global  |  Technology Research

    Connected Diabetes Care: Innovations and Growth Opportunities

    Continuous Glucose Monitoring, Artificial Pancreas Systems, and Novel Insulin Delivery Formulations to Transform the Future of Diabetes Management

    The preference for diabetes self-assessment using wearable CGMs instead of finger-stick blood sugar testing is increasing, especially in type 1 diabetics (T1D). HbA1c and time-in-range are currently the preferred biomarkers for diabetes monitoring applications. Emerging diet and fitness tracking apps help support general well-being and prevent the ...

    $4,950.00
  6. 12 Jun 2024  |  Global  |  Market Research

    Innovative AI-enabled Clinical Trial Companies: Strategic Profiling and Growth Opportunities

    The Integration of Real-world Insights into Trial Management is Propelling AI Adoption in Clinical Trials

    As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...

    $2,450.00
  7. 01 Mar 2024  |  North America  |  Market Research

    Global Orphan Drug Growth Opportunities

    Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

    In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

    $4,950.00